Last reviewed · How we verify
NCT06661239
Effect of the Benson Relaxation Technique on Clinical Outcomes of Oncology Patients Admitted to Intensive Care Units
NA trial testing benson relaxation in Oncology Patients in 60 participants. Completed in 1 August 2025.
1 August 2025
Quick facts
| Lead sponsor | Damanhour University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 60 |
| Start date | 1 November 2024 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- benson relaxation
- Routine care in unit
Conditions studied
- Oncology Patients — all drugs for Oncology Patients →
- Relaxation Program — all drugs for Relaxation Program →
Sponsor
Damanhour University
Who can join
Adults 18 to 60, any sex, with Oncology Patients or Relaxation Program. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The benson Relaxation Technique (BRT), developed by Dr. Herbert Benson, is a method aimed at reducing stress and anxiety through a series of simple steps designed to elicit the "Relaxation Response." This response is a physiological state that counteracts the harmful effects of stress, characterized by decreased heart rate, lower metabolism, and reduced breathing rate
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06661239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oncology Patients
Currently open trials in the same condition.
- NCT07443839 — Oncology Legal Navigation Study · NA · recruiting
Other Damanhour University trials
Trials by the same sponsor.
- NCT07307911 — Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy · Phase 2 · completed
- NCT07341893 — Sacubitril-valsartan in Patients With Heart Failure. · NA · recruiting
- NCT07063628 — Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity · completed
- NCT06849388 — Effect of HeartMath Intervention on Stress, Emotional Vitality and Sense of Coherence · NA · recruiting
- NCT07179302 — Pre- and Post-TAVI Patient Assessment: Advancing Outcome Precision in Aortic Valve Therapy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06661239 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Damanhour University
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06661239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing